Incyte (INCY) Q4 Earnings Miss Estimates

Group 1 - Incyte reported quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share, but showing an increase from $1.06 per share a year ago, resulting in an earnings surprise of -6.54% [1] - The company posted revenues of $1.18 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.63%, compared to year-ago revenues of $1.01 billion [2] - Incyte shares have increased approximately 7.3% since the beginning of the year, outperforming the S&P 500's gain of 2.5% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.24 on revenues of $1.02 billion, and for the current fiscal year, it is $6.17 on revenues of $4.64 billion [7] - The Medical - Biomedical and Genetics industry, to which Incyte belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]